BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

DISEASE CATEGORY: Cardiovascular INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury. The...
BioCentury | Jun 3, 2020

Third Rock-launched Pliant is latest biotech to climb on public debut

...CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin alpha(V)beta(1) (CD51/CD29) Integrin...
BioCentury | Jun 2, 2020

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

...Swedish company in any sector in 15 years to list on the exchange. Targets CD51 (CD29...
BioCentury | May 11, 2020

Third Rock-backed fibrosis company Pliant joins IPO queue

...$125 million at a valuation of $1.1 billion (see “ADC Renews Bid” ). Targets CD51 (CD29...
BioCentury | Mar 3, 2020

Pliant to advance rare fibrosis pipeline with Novartis-led $100M C round

...royalties (see "Pliant to Flesh Out Fibrosis Pipeline After NASH Deal" ). PLN-74809, a dual CD51/CD29...
...CD51/CD29 - Integrin α V β 1 Sandi Wong, Assistant Editor Pliant Therapeutics Inc. Novartis AG Integrin alpha(V)beta(6) Integrin alpha(V)beta(1) (CD51/CD29) idiopathic...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

...Two subsets -- one positive and one negative for FAP, and both expressing ACTA2 and CD29...
...2 smooth aorta muscle; BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17; CD29...
...β BioCentury Staff TeneoBio Inc. Institut Curie Institut National de la Sante et de la Recherche Medicale (INSERM) NIH Basilea Pharmaceutica Ltd. Integrin beta(1) (CD29) Tumor...
BioCentury | Nov 14, 2019
Targets & Mechanisms

Impaired wound healing: CD47’s latest safety hurdle?

...injury require further study, the researchers said. Targets: FAK - Focal adhesion kinase; Integrin β1 (CD29...
BioCentury | Oct 23, 2019
Company News

Pliant to flesh out fibrosis pipeline after NASH deal with Novartis

...transcriptional regulation of epithelial-to-mesenchymal cellular transition. Elizabeth S. Eaton, Staff Writer Pliant Therapeutics Inc. Novartis AG Integrin alpha(V)beta(6) Integrin alpha(V)beta(1) (CD51/CD29...
BioCentury | Sep 7, 2018
Company News

Osaka University grants Otsuka rights to MMG49

Osaka University (Osaka, Japan) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive, worldwide rights to patents associated with MMG49, a CAR T cell therapy that targets the active conformer of integrin β(7). The university will...
BioCentury | Aug 16, 2018
Distillery Therapeutics


INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
Items per page:
1 - 10 of 97